Get the Stockscreener App
41.30
4.02%
-1.73
After Hours:
40.00
-1.30
-3.15%
Avidity Biosciences Inc stock is traded at $41.30, with a volume of 1.02M.
It is down -4.02% in the last 24 hours and down -1.36% over the past month.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$43.03
Open:
$42.4
24h Volume:
1.02M
Relative Volume:
0.85
Market Cap:
$4.93B
Revenue:
$10.60M
Net Income/Loss:
$-252.45M
P/E Ratio:
-13.32
EPS:
-3.1
Net Cash Flow:
$-158.91M
1W Performance:
-8.49%
1M Performance:
-1.36%
6M Performance:
+53.76%
1Y Performance:
+409.88%
1-Day Range:
$41.02
$42.71
1-Week Range:
$41.02
$45.98
52-Week Range:
$6.79
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
41.30 | 4.93B | 10.60M | -252.45M | -158.91M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.73 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.34 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
617.49 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.01 | 32.63B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.20 | 28.10B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Charles Schwab Investment Management Inc. Purchases 197,065 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Alethea Capital Management LLC Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences Announces New Precision Cardiology Developme - GuruFocus.com
Myotonic dystrophy pipeline shows momentum - The Pharma Letter
Fmr LLC Has $773.86 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha
Avidity Biosciences to Present at Evercore ISI HealthCONx Conference | RNA Stock News - StockTitan
Royal Bank of Canada Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - MarketBeat
RBC Capital initiates Avidity Biosciences shares with Outperform rating By Investing.com - Investing.com Canada
Intech Investment Management LLC Makes New $1.70 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Victory Capital Management Inc. Purchases 11,367 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
RNA's SWOT analysis: promising pipeline drives biotech stock potential - Investing.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Avidity Biosciences Awards $43.65 Stock Options, RSUs to New Employees | RNA Stock News - StockTitan
Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences director Arthur Levin sells $139,972 in stock - Investing.com India
Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com Canada
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - MSN
Mutual of America Capital Management LLC Sells 19,252 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat
Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat
RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com
Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences unveils new cardiology development candidates - BioWorld Online
RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance
US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada
Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow
Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com
Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha
Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart
Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com
Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks
Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - Quantisnow
Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance
431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.58%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):